KBCols Sciences Pvt. Ltd. (Official Account)’s Post

Lithuanian startup Biomatter recently secured €6.5 million in seed funding to advance its generative AI platform for enzyme design. The funding round was led by Inventure and UVC Partners, with participation from existing investors and industry experts. This significant investment will enable Biomatter to enhance its technology and accelerate the development of novel enzymes for various applications. Biomatter, founded by Donatas Repečka, Laurynas Karpus, Rolandas Meškys, and Vykintas Jauniskis, focuses on creating new proteins and enzymes using AI, aiming to revolutionize industries such as health, sustainable manufacturing, and agriculture. Their technology offers a more efficient approach to enzyme design, overcoming traditional trial-and-error methods and broadening potential applications. Biomatter has already partnered with notable companies like Thermo Fisher Scientific and BASF to produce unique enzymes. With the newly raised funds, Biomatter plans to expand its platform capabilities and meet increasing customer demand. Their goal is to push the boundaries of enzyme design, contributing to advancements in medicine, chemical manufacturing, and food production. This investment marks a significant step forward in the development of AI-driven synthetic biology.

The S&T innovation ecosystem in the 21st century is rapidly changing- from being more knowledge-based to building infrastructure, it has now shifted to solving people’s problems. This makes it even more important for us to develop our science and technology innovation ecosystem in a way that it impacts millions of people. BIRAC has done fantastically well in setting up the 75 bio incubators around the country. These have become hubs for the people to get together, develop ideas and learn from each other. ~Rajesh Gokhale, Secretary, Department of Biotechnology, Chairman ,Biotechnology Industry Research Assistance Council (BIRAC) at #GlobalBioIndia2023 Biotechnology Industry Research Assistance Council (BIRAC) Invest India TiE Delhi-NCR Startup India MyGov India FICCI ABLE - Association of Biotechnology Led Enterprises Indian Venture and Alternate Capital Association (IVCA) Ministry of Ayush Manish Diwan

#GlobalBioIndia2023 is going to be a game changer. It is going to be an event that is different from the previous 2 editions.The innovation showcase the kind of participation the summit is going to see will ensure that we witness a mega show in December. In an era of confluence of #technology, where many disciplines converge, #Biotechnology will play a dominant role in achieving our goal of becoming the third largest #economy of the world. ~ Dr Jitendra Kumar, MD, BIRAC  at the #GlobalBioIndia2023 Invest India Biotechnology Industry Research Assistance Council (BIRAC) India DST TiE Delhi-NCR Startup India MyGov India FICCI ABLE - Association of Biotechnology Led Enterprises Indian Venture and Alternate Capital Association (IVCA)

Countdown Begins. Global Bio India 2023 Elmentoz Research Biotechnology Industry Research Assistance Council (BIRAC) KPMG India

I am a #scientist looking to learn more about #venturecapital Do you have any advice, resources or places I should look or people I should follow? I would love to increase the number of women-led businesses in biotech funded by venture capital, but I don't know much about the funding side. I know lots about the science side :) Coffee/tea on me for any leads. And thanks for reading! ___ #womeninstem #womeninscience #venturecapital #biotech #biotechnology

want to RAISE FUNDING for your BIOTECHNOLOGY STARTUP. Every Biotech startup is in dier need of assistance in financing and funds management. following are the main questions that every CEO asks itself. • Which characteristics of the industrial biotechnology sector make it an attractive sector for investors and which discourage investment? • What are the main drivers and barriers for investments in industrial biotechnology? • What are emerging trends in industrial biotechnology financing and investment area? • What are the capital requirements for R&D and infrastructure as well as non-classical financial sources? • What are industrial biotechnology specific market failures and the consequences? • Which indicators can be used for measuring trends in financing and investment? >>>> Well dont you worry guys<<<<<< I got you covered, Presenting you, A structured research approach using the existing FESTEL CAPITAL data base was used to prepare the paper for further discussion.More than 150 industrial biotechnology companies were analysed by desk research, interviewed or FESTEL CAPITAL had an open discussion  #biotechnology #startups #investment

A Training program on Innovation and Startup was organized for the students of PG Department of Biotechnology, Dwaraka Doss Goverdhan Doss Vaishnav College in association with IIC, at Golden Jubilee Biotech Park for Women Society on February 02, 2024.   Key takeaways from the training programme..   ·      Innovation and Startup at Golden Jubilee Biotech Park for Women Society ·      Technology and innovation are integral to the success of any startup or innovative organization. ·      The ability to think creatively and open-mindedly is essential ·      There is nothing more important than building and nurturing a talented team ·      The importance of flexibility and adaptability for individuals and organizations ·      It is important to embrace failure as a stepping stone towards success ·      A continuous learning process is essential to staying up-to-date on industry trends ·      It is essential to possess adaptability and resilience in order to succeed ·      Creating strong relationships with industry experts, mentors, and investors is essential for startup success   The students also got the opportunity to visit Adiuvo Diagnostics Pvt Ltd and MicroGo LLP, Designing Delivery Systems for Microbial Control unit. - PG Dept. of Biotech, DDGDVC #ddgdvc #dgvc #dgvcbiotech #biotechnology #lifesciences  #technosaviour #sustainability #sustainableproducts #innovation #startups #startupinnovation #incubationprogram

One of the reasons I truly enjoy being part of the BioCentury Inc. team is the constant exposure to cutting-edge developments and insights that keep me at the forefront of the industry. 💡🔬 My personal read of the week: This fascinating article by BioCentury highlights the Series A companies that are shaping the future of biotech in 2023. It's a compelling read that showcases the innovation and potential within our industry. #biotech #innovation #SeriesA

Biotech has been growing rapidly over the last few years, and all indicators show that this growth is likely to increase. Research indicates that the industry is likely to grow at a compound annual growth rate (CAGR) of 13.96% between 2023 and 2030. Biotech #startups generally create useful products that will help improve the state of humanity as a whole. This means that, more often than not, #biotech products fulfill a need and are considered marketable. As long as a product has met regulatory requirements and made it through mandatory testing, there are numerous reasons to feel positively about your investment. For the most part, #biotechnology is an exciting investment opportunity. However, as with all stocks, there are potential risks to consider, as well as potential rewards.

🇨🇵 (2/2) France is Investing in Biotech Innovation: Last week, I attended Viva Technology 2024 and discovered that France represented more biotech-based startups than any other country. Let’s dive into the CNRS - Centre national de la recherche scientifique stand, one of the biggest scientific institutions in French research: LACTIPS TECH: Lactips develops bioplastics from milk protein (casein). Their products are 100% bio-based, biodegradable, and water-soluble, making them an environmentally friendly alternative to traditional plastics. These bioplastics can be used for various applications, including packaging for detergents, food, and other products that benefit from water solubility and biodegradability. BUSINESS: Lactips has secured funding with 4 rounds and have the support from the French government and private investors. Their objective is to scale up production and expand its market presence, by building their own manufacturing site and exploring new applications for their bioplastics in different industries. They may also expand its technology to other protein sources, which would decrease the cost of milk-based plastics. HEPHAISTOS-Pharma (Which I had not the opportunity to speak with but is worth to share) TECH: Their aim is to treat non-respomdomg cancers, or "cold tumors", by developing the next generation of immunomodulators. Its strategy includes a mAb which should block the passivation pathways of the immune cells within the tumor to make it sensitive to treatment again. BUSINESS: With their last fundraising round, they raised €10.3 M to push their product to the clinical stage. Furthermore, half of it involves non-dilutive capitalization, which shows the great potential of their ONCO-Boost treatment. That's all for the CNRS, but there were more French exhibitors, which I will cover in the following weeks. I hope to see how these companies perform in the future and wish you the best. I look forward to connecting with fellow attendees/presenters. Feel free to reach out if you want to discuss anything! (image with all the presented stands, reprinted from the CNRS site) #Biotech #Innovation #France #VivaTech2024 #CNRS #Pharma #Startups #TechTrends #ScienceAndTechnology #ResearchAndDevelopment #BiotechStartups